[go: up one dir, main page]

EP3672587A4 - Pharmazeutische zusammensetzungen zur behandlung von augenerkrankungen - Google Patents

Pharmazeutische zusammensetzungen zur behandlung von augenerkrankungen Download PDF

Info

Publication number
EP3672587A4
EP3672587A4 EP18850117.5A EP18850117A EP3672587A4 EP 3672587 A4 EP3672587 A4 EP 3672587A4 EP 18850117 A EP18850117 A EP 18850117A EP 3672587 A4 EP3672587 A4 EP 3672587A4
Authority
EP
European Patent Office
Prior art keywords
treatment
pharmaceutical compositions
eye diseases
diseases
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18850117.5A
Other languages
English (en)
French (fr)
Other versions
EP3672587A1 (de
Inventor
Ping Chang
Zhenze Hu
Yuanyuan TAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhodes Technologies Inc
Original Assignee
Rhodes Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhodes Technologies Inc filed Critical Rhodes Technologies Inc
Publication of EP3672587A1 publication Critical patent/EP3672587A1/de
Publication of EP3672587A4 publication Critical patent/EP3672587A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP18850117.5A 2017-08-27 2018-08-10 Pharmazeutische zusammensetzungen zur behandlung von augenerkrankungen Pending EP3672587A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762550642P 2017-08-27 2017-08-27
US201762609752P 2017-12-22 2017-12-22
PCT/US2018/046331 WO2019045994A1 (en) 2017-08-27 2018-08-10 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OPHTHALMIC CONDITIONS

Publications (2)

Publication Number Publication Date
EP3672587A1 EP3672587A1 (de) 2020-07-01
EP3672587A4 true EP3672587A4 (de) 2021-05-19

Family

ID=65525886

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18850117.5A Pending EP3672587A4 (de) 2017-08-27 2018-08-10 Pharmazeutische zusammensetzungen zur behandlung von augenerkrankungen

Country Status (8)

Country Link
US (2) US11786463B2 (de)
EP (1) EP3672587A4 (de)
KR (1) KR102652605B1 (de)
CN (2) CN117752606A (de)
AU (1) AU2018323861B2 (de)
CA (1) CA3072768C (de)
IL (1) IL272601B2 (de)
WO (1) WO2019045994A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
WO2019152736A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
EP3864000A4 (de) 2018-10-10 2022-08-10 Treehouse Biosciences, Inc. Synthese von cannabigerol
WO2022091051A1 (en) * 2020-10-31 2022-05-05 Ai Pharmaceuticals Jamaica Limited Cannabis compositions and emulsions
CA3195291A1 (en) * 2022-04-13 2023-10-13 Caravel Therapeutics, Inc. Preservative-free ophthalmic pharmaceutical emulsion and its application
CN115006404A (zh) * 2022-08-09 2022-09-06 昆药集团股份有限公司 一种具有视神经保护功效的药物组合物及其应用
EP4486338A2 (de) * 2022-11-04 2025-01-08 Qlaris Bio, Inc. Topische okulare verabreichung von cromakallim
WO2024145493A1 (en) * 2022-12-29 2024-07-04 Adtech Pharma, Inc. Pharmaceutical compositions comprising nabilone for the treatment of ophthalmic conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0521799A1 (de) * 1991-07-05 1993-01-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Augenarzneimittel
US20150045282A1 (en) * 2008-10-31 2015-02-12 The University Of Mississippi Compositions containing delta-9-thc-amino acid esters and process of preparation
US20160143977A1 (en) * 2014-11-25 2016-05-26 Allergan, Inc. Stabilized omega-3 ophthalmic compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509005B1 (en) * 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
AU2004249669B2 (en) * 2003-05-20 2008-05-22 The University Of Tennessee Research Foundation Cannabinoid derivatives, methods of making, and use thereof
UA92498C2 (ru) * 2005-06-16 2010-11-10 Евро-Селтик С.А. Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US9265724B2 (en) * 2005-11-07 2016-02-23 Ram B. Murty Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
TW200806284A (en) * 2006-03-31 2008-02-01 Alcon Mfg Ltd Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
US8039509B2 (en) * 2006-11-10 2011-10-18 Johnson Matthey Public Limited Company Composition comprising (−)-Δ9-trans-tetrahydrocannabinol
CA2706517C (en) * 2007-11-28 2015-11-17 Commonwealth Scientific And Industrial Research Organisation Nanoemulsion as delivery vehicles for active components
US20100303915A1 (en) * 2009-06-02 2010-12-02 Abbott Medical Optics Inc. Therapeutic opthalmic emulsions
CN104144677B (zh) * 2012-01-20 2016-11-23 阿拉塔纳医疗有限公司 滴眼剂组合物
TR201808197T4 (tr) * 2013-03-14 2018-07-23 Eyecro Llc Mikroemülsiyon topikal dağıtım platformu.
CN106061490A (zh) * 2013-10-09 2016-10-26 列奥尼达斯·A·约翰逊 一种治疗和预防眼部疾病症状或体征的方法及组合物
EP3270896A4 (de) * 2015-03-19 2018-09-12 One World Cannabis Ltd. Präparate von cannabisemulsionen und verfahren dafür

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0521799A1 (de) * 1991-07-05 1993-01-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Augenarzneimittel
US20150045282A1 (en) * 2008-10-31 2015-02-12 The University Of Mississippi Compositions containing delta-9-thc-amino acid esters and process of preparation
US20160143977A1 (en) * 2014-11-25 2016-05-26 Allergan, Inc. Stabilized omega-3 ophthalmic compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VANDAMME TH F: "Microemulsions as ocular drug delivery systems: recent developments and future challenges", PROGRESS IN RETINAL AND EYE RESEARCH, OXFORD, GB, vol. 21, no. 1, 1 January 2002 (2002-01-01), pages 15 - 34, XP002630484, ISSN: 1350-9462 *

Also Published As

Publication number Publication date
IL272601B1 (en) 2024-11-01
CA3072768A1 (en) 2019-03-07
CN117752606A (zh) 2024-03-26
CN111587111A (zh) 2020-08-25
US11786463B2 (en) 2023-10-17
CN111587111B (zh) 2023-12-19
WO2019045994A1 (en) 2019-03-07
CA3072768C (en) 2024-06-11
AU2018323861A1 (en) 2020-03-19
KR102652605B1 (ko) 2024-03-28
US20210299046A1 (en) 2021-09-30
IL272601A (en) 2020-03-31
AU2018323861B2 (en) 2023-08-17
IL272601B2 (en) 2025-03-01
US20230398073A1 (en) 2023-12-14
KR20200044874A (ko) 2020-04-29
EP3672587A1 (de) 2020-07-01

Similar Documents

Publication Publication Date Title
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
EP3263132C0 (de) Zusammensetzung zur behandlung von il-6-assoziierten erkrankungen
EP3498297C0 (de) Pharmazeutische zusammensetzung zur behandlung von autismus
EP3672587A4 (de) Pharmazeutische zusammensetzungen zur behandlung von augenerkrankungen
EP3890725A4 (de) Zusammensetzungen zur behandlung von hauterkrankungen
EP3597208A4 (de) Pharmazeutische zusammensetzung mit atpif1 zur behandlung von diabetes
EP3621593A4 (de) Pharmazeutische zusammensetzungen und verfahren zur behandlung von herz-kreislauf-erkrankungen
EP3492096A4 (de) Pharmazeutische zusammensetzung zur behandlung von augenerkrankungen mit cas9-proteins und guide-rna
EP3630102C0 (de) Formulierungen zur behandlung von posttraumatischer belastungsstörung
EP3572095A4 (de) Pharmazeutische zusammensetzung zur behandlung von mit htlv-1-assoziierter myelopathie
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EP3500278C0 (de) Zusammensetzungen zur behandlung von erkrankungen mit rekombinantem selbstkomplementärem adeno-assoziiertem virus
EP3493823C0 (de) Postbiotika-basierte zusammensetzung zur behandlung von augenentzündungen
EP3720509A4 (de) Globingentherapie zur behandlung von hämoglobinopathien
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EP3801465A4 (de) Demethylierung zur behandlung von augenerkrankungen
EP3556402A4 (de) Pharmazeutische zusammensetzung zur prävention oder behandlung von hepatitis b
EP3793544A4 (de) Pharmazeutische zusammensetzungen zur behandlung von krebs
EP3488850A4 (de) Neuartige verwendung von gzd824 und pharmazeutisch akzeptable salze davon zur behandlung von krankheiten
EP3634394A4 (de) Zusammensetzungen zur behandlung von neurodegenerativen erkrankungen
EP3638252A4 (de) Stichabhängige aktivatoren zur behandlung von krankheiten
EP3612133A4 (de) Implantierbare gerüste zur behandlung von sinusitis
EP3703674A4 (de) Phosphorylcholin-tuftsin-konjugate zur behandlung von augenentzündungen
EP3672593C0 (de) Arzneimittel zur behandlung von gefässverengenden erkrankungen oder störungen
EP3639842A4 (de) Pharmazeutische zusammensetzung mit gly-thymosin 4 (gly-t 4) zur behandlung des trockenen auges

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200316

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40033754

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20210419

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/352 20060101AFI20210413BHEP

Ipc: A61K 9/107 20060101ALI20210413BHEP

Ipc: A61K 47/26 20060101ALI20210413BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230505

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250225